Summary
Boston Scientific Corporation (BSX) has filed an 8-K report on February 1, 2023, primarily to announce its fourth quarter and full-year financial results for the period ending December 31, 2022. The report itself does not contain the detailed financial results but rather furnishes a press release (Exhibit 99.1) where these results are disclosed. Investors should refer to this press release for comprehensive information regarding the company's performance in the fourth quarter and the entirety of 2022. The filing is procedural, confirming the public release of this important financial information.
Key Highlights
- 1Boston Scientific Corporation released its Q4 and full-year 2022 financial results via a press release filed on February 1, 2023.
- 2The 8-K filing serves as notification and includes the press release as an exhibit.
- 3Investors need to consult the furnished press release (Exhibit 99.1) for specific financial performance details.
- 4The information provided is not deemed 'filed' for purposes of Section 18 of the Exchange Act, meaning it's not subject to liabilities under that specific section.
- 5This filing is a standard procedure for announcing material financial outcomes.
Frequently Asked Questions
The detailed financial results are provided in the press release issued by Boston Scientific Corporation on February 1, 2023, which is furnished as Exhibit 99.1 to this 8-K filing. You should refer to that document for specific figures and performance metrics.
This 8-K filing is primarily to formally report that Boston Scientific has publicly issued its financial results for the fourth quarter and full year 2022. It acts as a notification to the SEC and investors, with the actual results contained within the attached press release.
No, the 8-K filing itself does not contain the detailed financial data. It references and includes a press release (Exhibit 99.1) which contains the financial results. Investors should review Exhibit 99.1 for the performance information.